Free tool
FAERS Monitor: Ibsrela
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211801 or its brand name (Ibsrela, Tenapanor Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3,714
Serious
1,104
30% of reports
Hospitalization
627
Death reported
114
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea1,288
- product use issue444
- inappropriate schedule of product administration401
- therapy interrupted294
- product use in unapproved indication261
- abdominal distension247
- drug ineffective219
- off label use209
- insurance issue208
- intentional underdose179
- abdominal pain upper167
- abdominal pain148
- nausea147
- flatulence135
- underdose125
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 42 |
| 2023 | 103 |
| 2024 | 353 |
| 2025 | 500 |
| 2026 | 2,709 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,445 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intentional underdoseSignal | 179 | 142.2 | 123.1 | 24,359 |
| insurance issueSignal | 208 | 78.1 | 68.4 | 15,547 |
| therapy interruptedSignal | 294 | 23.4 | 21.0 | 6,274 |
| flatulenceSignal | 135 | 13.5 | 11.4 | 1,552 |
| abdominal distensionSignal | 247 | 13.4 | 11.9 | 2,836 |
| product use issueSignal | 444 | 13.4 | 12.3 | 5,120 |
| inappropriate schedule of product administrationSignal | 401 | 12.6 | 11.5 | 4,309 |
| diarrhoeaSignal | 1,288 | 11.3 | 10.8 | 12,467 |
| underdoseSignal | 125 | 9.7 | 8.2 | 970 |
| product use in unapproved indicationSignal | 261 | 6.0 | 5.3 | 1,086 |
| abdominal pain upperSignal | 167 | 4.6 | 4.0 | 471 |
| abdominal painSignal | 148 | 3.6 | 3.1 | 279 |
| off label use | 209 | 1.4 | 1.2 | 20 |
| nausea | 147 | 1.1 | 0.9 | 0 |
| drug ineffective | 219 | 0.9 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.